Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials

Respirology

Volumn 21, Issue 2, 2016, Pages 378-385

  Jullian Desayes, Ingrid ^a,b   Tamisier, Renaud ^a,b   Zarski, Jean Pierre ^c   Aron Wisnewsky, Judith ^c,d   Launois Rollinat, Sandrine H ^a,b   Trocme, Candice ^e   Levy, Patrick ^a,b   Joyeux Faure, Marie ^a,b   Pepin, Jean Louis ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b EFCR   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e INSERM   (France)

Author keywords

comorbidities; continuous positive airway pressure treatment; intermittent hypoxia; liver disease; obstructive sleep apnoea

Indexed keywords

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SLEEP DISORDERED BREATHING; BLOOD; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

BIOLOGICAL MARKER;

BIOMARKERS; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84955301378     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12672     Document Type: Article

References (33)

1. Lévy P, Tamisier R, Minville C, Launois S, Pépin J-L,. Sleep apnoea syndrome in 2011: current concepts and future directions. Eur. Respir. Rev. 2011; 20: 134-146.
2. Lévy P, Bonsignore MR, Eckel J,. Sleep, sleep-disordered breathing and metabolic consequences. Eur. Respir. J. 2009; 34: 243-260.
3. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot J-L, Basdevant A, Bedossa P, Clément K, Pépin JL,. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J. Hepatol. 2012; 56: 225-233.
4. Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, Afendy M, Fang Y, Elariny H, Goodman Z, Younossi ZM,. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int. 2008; 28: 1080-1086.
5. Sanyal AJ,. NASH: a global health problem. Hepatol. Res. 2011; 41: 670-674.
6. Cohen JC, Horton JD, Hobbs HH,. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523.
7. Hashimoto E, Taniai M, Tokushige K,. Characteristics and diagnosis of NAFLD/NASH. J. Gastroenterol. Hepatol. 2013; 28: 64-70.
8. Edmison J, McCullough AJ,. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin. Liver Dis. 2007; 11: 75-104.
9. Perazzo H, Poynard T, Dufour J-F,. The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. Clin. Liver Dis. 2014; 18: 233-248.
10. Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T,. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev. Mol. Diagn. 2007; 7: 481-490.
11. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T,. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
12. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T,. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J. Gastrointestin. Liver Dis. 2008; 17: 187-191.
13. Minville C, Hilleret M-N, Tamisier R, Aron-Wisnewsky J, Clement K, Trocme C, Borel JC, Lévy P, Zarski JP, Pépin JL,. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea. Chest 2014; 145: 525-533.
14. Shpirer I, Copel L, Broide E, Elizur A,. Continuous positive airway pressure improves sleep apnea associated fatty liver. Lung 2010; 188: 301-307.
15. Norman D, Bardwell WA, Arosemena F, Nelesen R, Mills PJ, Loredo JS, Lavine JE, Dimsdale JE,. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 2008; 31: 121-126.
16. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R,. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes. Rev. 2013; 14: 417-431.
17. Chin K, Nakamura T, Takahashi K, Sumi K, Ogawa Y, Masuzaki H, Muro S, Hattori N, Matsumoto H, Niimi A, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am. J. Med. 2003; 114: 370-376.
18. Kohler M, Pepperell JCT, Davies RJO, Stradling JR,. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration 2009; 78: 141-146.
19. Sivam S, Phillips CL, Trenell MI, Yee BJ, Liu PY, Wong KK, Grunstein RR,. Effects of 8 weeks of continuous positive airway pressure on abdominal adiposity in obstructive sleep apnoea. Eur. Respir. J. 2012; 40: 913-918.
20. Farré R, Hernández L, Montserrat JM, Rotger M, Ballester E, Navajas D,. Sham continuous positive airway pressure for placebo-controlled studies in sleep apnoea. Lancet 1999; 353: 1154.
21. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American academy of sleep medicine. J. Clin. Sleep Med. 2012; 8: 597-619.
22. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 2005; 4: 10.
23. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 34.
24. Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7: e30325.
25. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM,. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am. J. Epidemiol. 2013; 178: 38-45.
26. Hoyos CM, Killick R, Yee BJ, Phillips CL, Grunstein RR, Liu PY,. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. Thorax 2012; 67: 1081-1089.
27. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR,. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974.
28. Coughlin SR, Mawdsley L, Mugarza JA, Wilding JPH, Calverley PMA,. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur. Respir. J. 2007; 29: 720-727.
29. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-1685.
30. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
32. Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Saif H, Broderick P, et al. CPAP, weight loss, or both for obstructive sleep apnea. N. Engl. J. Med. 2014; 370: 2265-2275.
33. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C,. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826.